Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma 9Lymphoma, T-Cell 7Lymphoma, Follicular 7Recurrence 6Lymphoma, Non-Hodgkin 6Lymphoma, T-Cell, Peripheral 4Leukemia 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Hereditary Sensory and Autonomic Neuropathies 3Hematologic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Immunoblastic Lymphadenopathy 2Head and Neck Neoplasms 2Enteropathy-Associated T-Cell Lymphoma 2Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphoid 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Burkitt Lymphoma 1Advanced Solid Tumors 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 4venetoclax 3ruxolitinib 3Cytarabine 3Alemtuzumab 3itacitinib 2duvelisib 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Carmustine 2thymoglobulin 1romidepsin 1niraparib 1nelarabine 1letermovir 1ibrutinib 1Tacrolimus 1Sensitivity and Specificity 1Mitoxantrone 1Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, T-Cell × duvelisib × Clear all
NCT05010005 2026-04-09

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
70 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT06810778 2025-07-15

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting
12 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡